1) APACHEⅡ score
APACHEⅡ积分
1.
Effects of continuous veno-venous hemofiltration on serum C-reactive protein level and APACHEⅡ score in patients with multiple organ dysfunction syndrome
连续性静脉-静脉血液滤过对多脏器功能障碍综合征APACHEⅡ积分及C反应蛋白的影响
2) APACHE II models
APACHEⅡ积分模型
3) APACHEⅡ score
APACHEⅡ评分
1.
Clinical value of APACHEⅡ score system and organ function monitoring in cases with multiple trauma;
APACHEⅡ评分及器官功能监测在多发性创伤治疗中的价值
2.
Objective: To investigate the relationship between the changes of platelet in critically ill patients and APACHEⅡ score.
目的:研究危重病患者血小板水平变化与APACHEⅡ评分的关系。
3.
And the data of FIB and D-D of SAP group have positive correlation with the APACHEⅡ score (r=0.
05),并且SAP患者FIB和D-D值与APACHEⅡ评分值之间存在正相关关系(r=0。
4) Acute Physiology and Chronic Health Evaluation Ⅱ/Ⅲ(APACHEⅡ/Ⅲ)
APACHEⅡ/Ⅲ评分
1.
Objective To compare the clinical value of Acute Physiology and Chronic Health Evaluation Ⅱ/Ⅲ(APACHEⅡ/Ⅲ)system and Simple Acute Physiology Score Ⅱ(SAPSⅡ)system in predicting the prognosis of liver failure.
目的比较APACHEⅡ/Ⅲ评分和SAPSⅡ评分系统评估我国肝衰竭患者预后的临床应用价值。
5) APACHEⅡscore
APACHEⅡ评分
1.
Results The APACHEⅡscore was 13-67(33.
方法对156例重型肝炎患者应用APACHEⅡ评分,分析评分对预后的预测价值,并根据评分结果指导护理工作安排和护理措施的制定。
2.
The values of APACHEⅡscore were calculated and the incidence of upper gast.
方法对2005年1月至2006年11月间,发病时间≤48h的108例SAP患者,采用试纸法检测胃液pH值变化,观测SAP患者人院时及入院后72h平均胃内pH值及pH值>4、>6的时点数变化,并与APACHEⅡ评分及上消化道出血进行比较。
3.
Methods:193elder critical patients were enrolled in this study,and allocated into groupⅠ(<15scores),groupⅡ(15～20scores)and groupⅢ(>20scores)according to APACHEⅡscore.
方法:将急诊193例患者,入院时进行APACHEⅡ评分及入院第1、3、7、10天进行血小板计数检测。
6) APACHEⅡ
APACHEⅡ评分
1.
The Study of Correlation between The Inflammatory Cytokines and APACHEⅡ in Acute Poisoning;
急性中毒患者细胞因子水平与APACHEⅡ评分相关性研究
2.
The APACHEⅡ was detected in 48 patients admitted at ICU at the first day.
方法根据美国胸科医学会(ACCP)和危重病医学会(SCCM)制定的标准诊断,以2003年4月～2005年3月广州中医药大学第一附属医院48例符合SIRS诊断的ICU患者为研究对象,取得患者中医四诊资料,进行辨证,确定证型;同时进行APACHEⅡ评分。
3.
Platelet count and APACHEⅡ scores were performed immediately after hospitalization and 7?14 days later.
入院当天及第7、14天检查血小板和进行APACHEⅡ评分。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条